Immatics Biotechnologies lands €1.1bn deal with GSKUS-German immunooncology specialist Immatics Biotechnologies GmbH has licensed two of its TCR-T programs to GlaxoSmithKline for US$50m upfront. more ➔
KKR backs Belgian tech provider Univercells SA Univercells S.A. cashes in up to €50m from the KKR subsidiary Gamma Bioscience to advance its gene and cell therapy manufacturing platform. more ➔
EU diagnostic labs prepared for Sars-CoV-2Shortly before a EU health ministers discuss the spread of the Chinese coronavirus, EU diagnostic labs have considered themselves prepared for a possible Sars-CoV-2 epidemic. more ➔
PharmaMar/Jazz Pharmaceuticals get NDA priority for lung cancer drugPharmaMar and Jazz Pharmaceuticals have received FDA Priority Review of a NDA for lurbinectedin in relapsed SCLC (Small Cell Lung Cancer). more ➔
Diabetes combo improves regeneration of beta cellsUsing a combination of approved diabetes drugs, a Swiss-US research team was able to support the regeneration of insulin-secreting cells in the pancreas. more ➔
JAKPot for treating bone loss Researchers report that JAK inhibitors – a class of approved anti-inflammatory drugs – prevented bone loss in mice with osteoporosis and two patients with rheumatoid arthritis. more ➔
Mereo BioPharma raise money to back Phase III trialsMereo BioPharma has entered into a $5m convertible equity financing with Novartis and a $28m securities purchase agreement with Aspire Capital Fund. more ➔
Stilla raises €20m in series B financing roundFrench Stilla Technologies SA raised €20m in a Series B funding to boost digital PCR-based genetic testing. more ➔
BIH scientists optimise CRISPR gene scissorsTargeted genome editing using the CRISPR-Cas9 system is easy to use but far from being perfect. Computer calculated modification of CRISPR activity can reduce "off-target effects". more ➔
Azafaros BV raises €25m in Series A roundDutch biotech Azafaros B.V. has closed a €25m Series A financing round. more ➔
